Novartis’ Sandoz to pay $195m to settle price-fixing case
Antitrust probes have targeted the biggest names in the industry, including Mylan and Teva
03 March 2020 - 20:57
Washington — Novartis’s Sandoz unit agreed to pay $195m to settle US criminal charges that it conspired with other pharmaceutical companies to fix prices of generic drugs, the most significant settlement to come from a long-running justice department investigation.
Sandoz conspired with four of its competitors between 2013 and 2015 to rig drug prices, the department said Monday. The settlement marks the largest penalty obtained by the US in a domestic cartel case, the government said. Sandoz agreed to co-operate with the antitrust division’s continuing investigation...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.